As Noridian Administrative Services takes over Medicare Jurisdiction E from Palmetto GBA, many in the laboratory industry wondered what would happen to the molecular diagnostic service (MolDx) program that Palmetto had implemented in that region last year. Now, we know: Palmetto will continue to administer the MolDx program in JE (formerly J1). In addition, Palmetto is deploying the MolDx program in J11, which is being renamed Jurisdiction M. J1/JE covers California, Nevada, and Hawaii, as well as the U.S. territories of American Samoa, Guam, and the Northern Mariana Islands. J11/JM covers North Carolina, South Carolina, Virginia, and West Virginia. In an e-mail to National Intelligence Report, Mike Barlow, vice president, Palmetto GBA, confirms that the MolDx program will remain intact in JE. “Noridian has republished the Molecular Diagnostic Testing (MDT) policy and the requirement to register and submit new testing for technical assessment of clinical utility and refers test producers to the MolDx website for detailed program information (www.palmettogba.com/MolDx),” writes Barlow. “We (Palmetto GBA as MolDx) will continue to use the test submitted dossier information to determine clinical utility and reimbursement for those tests reviewed. “We are deploying the program in J11 and will be developing a master edit file,”…
